BR9808933A - Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo - Google Patents

Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo

Info

Publication number
BR9808933A
BR9808933A BR9808933-1A BR9808933A BR9808933A BR 9808933 A BR9808933 A BR 9808933A BR 9808933 A BR9808933 A BR 9808933A BR 9808933 A BR9808933 A BR 9808933A
Authority
BR
Brazil
Prior art keywords
acetate
microcapsules
implants
active substance
substance
Prior art date
Application number
BR9808933-1A
Other languages
English (en)
Inventor
Marc Pellet
Chantal Roume
Original Assignee
Pharma Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9808933(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9704837A external-priority patent/FR2762318B1/fr
Priority claimed from FR9803666A external-priority patent/FR2776516B1/fr
Application filed by Pharma Biotech filed Critical Pharma Biotech
Publication of BR9808933A publication Critical patent/BR9808933A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçãO SOB FORMA DE MICROCáPSULAS OU DE IMPLANTES, PROCESSO DE PREPARAçãO DE UMA SUBSTâNCIA HIDROSSOLúVEL, SUBSTâNCIA ATIVA, ACETATO DE TRIPTORELINA, ACETATO DE LANREOTìDEO, OU ACETATO DE OCTREOTìDEO, E RNA DE FILAMENTO DUPLO". A invenção refere-se a composições sob forma de microcápsulas ou implantes, compreendendo um excipiente ou uma mistura de excipientes polímeros ou copolímeros biodegradáveis de viscosidade inerente compreendida entre 0,5 dl/g e 1,6 dl/g em CHCI~ 3~, e uma substância ativa ou uma mistura de substâncias ativas, as referidas microcápsulas ou implantes podendo liberar a substância ativa ou a mistura de substâncias ativas durante um período prolongado podendo ir até três meses ou mais. Estas composições podem igualmente comportar um princípio ativo apresentando uma superfície especíifica elevada.
BR9808933-1A 1997-04-18 1998-04-17 Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo BR9808933A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9704837A FR2762318B1 (fr) 1997-04-18 1997-04-18 Compositions presentant une liberation prolongee et leur procede de preparation
FR9803666A FR2776516B1 (fr) 1998-03-25 1998-03-25 Compositions presentant une liberation prolongee et leur procede de preparation
PCT/FR1998/000773 WO1998047489A1 (fr) 1997-04-18 1998-04-17 Compositions presentant une liberation prolongee et leur procede de preparation

Publications (1)

Publication Number Publication Date
BR9808933A true BR9808933A (pt) 2000-08-01

Family

ID=26233477

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808933-1A BR9808933A (pt) 1997-04-18 1998-04-17 Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo

Country Status (23)

Country Link
US (2) US6217893B1 (pt)
EP (1) EP0980240B1 (pt)
JP (1) JP4557312B2 (pt)
CN (2) CN1144584C (pt)
AR (2) AR012448A1 (pt)
AT (1) ATE389388T1 (pt)
AU (1) AU741964B2 (pt)
BR (1) BR9808933A (pt)
CA (1) CA2286575C (pt)
CZ (1) CZ297078B6 (pt)
DE (1) DE69839264T2 (pt)
DK (1) DK0980240T3 (pt)
ES (1) ES2303353T3 (pt)
HK (1) HK1027983A1 (pt)
HU (1) HUP0004297A2 (pt)
IL (1) IL132217A (pt)
MY (1) MY118835A (pt)
NO (2) NO327999B1 (pt)
PL (1) PL196771B1 (pt)
PT (1) PT980240E (pt)
RU (1) RU2198678C2 (pt)
TW (1) TW577759B (pt)
WO (1) WO1998047489A1 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6303138B1 (en) * 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2002083176A2 (en) * 2001-04-17 2002-10-24 University Of Sheffield Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
JP2006504694A (ja) * 2002-09-18 2006-02-09 サントル・オスピタリエ・ドゥ・リュニヴェルシテ・ドゥ・モントリオール・（シー・エイチ・ユー・エム） Ｇｈｒｈ類似体
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7314859B2 (en) * 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2519779A1 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
WO2004089279A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
PT1615959E (pt) * 2003-04-10 2013-08-29 Evonik Corp Um método para a produção de micropartículas à base de emulsão
EP1620060B1 (en) * 2003-04-29 2010-03-24 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US8871269B2 (en) * 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
WO2005047334A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Igg fc fragment for a drug carrier and method for the preparation thereof
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CN1968700A (zh) * 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
RU2407751C2 (ru) 2004-10-27 2010-12-27 Юниверсити Оф Денвер Аналоги адренокортикотропного гормона и относящиеся к ним методы
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006092607A1 (en) * 2005-03-02 2006-09-08 The Secretary Of State For Defence Pharmaceutical composition
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
KR20130024987A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
ES2397712T3 (es) * 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
JP2010522196A (ja) * 2007-03-22 2010-07-01 アルカームズ，インコーポレイテッド コアセルベーション工程
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
KR101631475B1 (ko) 2007-06-06 2016-06-20 데비오팜 리서치 ＆ 매뉴팩처링 에스아 마이크로 입자로 구성되는 저속 방출 약학 조성물
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
ES2522342T3 (es) * 2008-01-30 2014-11-14 Novartis Ag Formulación de liberación sostenida que comprende octreótido y tres polímeros lineales de polilactida-co-glicolida
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP3685837A1 (en) * 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
JP5916622B2 (ja) * 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
IT1402654B1 (it) * 2010-09-20 2013-09-13 Cid S R L Composizione per il rilascio di principi attivi da dispositivi di impianto
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103163258B (zh) * 2011-12-09 2015-09-23 山东绿叶制药有限公司 一种测定痕量曲普瑞林的方法
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
JP6151725B2 (ja) * 2012-03-08 2017-06-21 コンセホ・スペリオール・デ・インベスティガシオネス・シエンティフィカスＣｏｎｓｅｊｏ Ｓｕｐｅｒｉｏｒ Ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｃｉｅｎｔｉｆｉｃａｓ フォトクロミック特性を有するコーティング、そのコーティングの製造方法、ならびに光学物品および光沢表面に適用可能なそれらの使用
WO2013164380A1 (en) 2012-05-03 2013-11-07 Janssen R&D Ireland Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
RU2506269C1 (ru) * 2012-08-03 2014-02-10 Татьяна Георгиевна Емельянова Фармацевтическая композиция, содержащая физиологически активные гептапептиды, обладающие противосудорожным, анксиолитическим, центральным противовоспалительным и анальгетическим, а также антиалкогольным действием
RU2694901C2 (ru) * 2013-04-18 2019-07-18 Шаньдун Луе Фармасьютикал Ко., Лтд Фармацевтические композиции микросфер гозерелина с пролонгированным высвобождением
CN103230624A (zh) * 2013-05-02 2013-08-07 复旦大学附属上海市第五人民医院 一种用于微创埋线治疗的植入材料
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
CN107690333B (zh) * 2015-06-10 2021-12-17 赢创运营有限公司 制备包含人凝血因子蛋白和乳酸聚合物的粉末的方法
CN107224571A (zh) * 2016-03-23 2017-10-03 张巍 一种具有坐骨神经保护功能的plga复合微球
ITUA20162094A1 (it) 2016-03-29 2017-09-29 Cid S P A Perfezionamenti negli stent per il rilascio di principi attivi
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
CN107375910B (zh) * 2017-07-12 2020-03-24 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 PTHrP在制备治疗男性性腺功能低下综合征中的应用
CN110547969A (zh) * 2019-09-03 2019-12-10 杭州诺泰澳赛诺医药技术开发有限公司 一种高比表面积纳米级缓释微粉的生产工艺及设备
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
CN112156170B (zh) * 2020-11-03 2022-10-21 北京康欣东弘医药科技有限公司 可供皮下注射的曲普瑞林缓释微球及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US5021554A (en) * 1989-02-24 1991-06-04 Eli Lilly And Company Process for protein particle size reduction using a fluid-energy mill
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
GB2246514B (en) 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
DE4041563A1 (de) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DE4223169C1 (de) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
FR2693905B1 (fr) 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
HU220137B (hu) * 1993-01-06 2001-11-28 Kinerton Ltd. Biológiailag lebontható poliészterek és biológiailag aktív polipeptidek ionos molekuláris konjugátumai, eljárás ezek előállítására és eljárás mikrorészecskék előállítására
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
CA2218074C (en) * 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
DK0831787T3 (da) * 1995-06-07 2001-12-17 Alkermes Inc Sammensætning til vedvarende frigivelse af humant væksthormon
WO1997026869A1 (en) * 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Novel 'burst-free' sustained release poly-(lactide/glycolide) microspheres
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation

Also Published As

Publication number Publication date
IL132217A (en) 2004-08-31
NO20080803L (no) 1999-11-15
RU2198678C2 (ru) 2003-02-20
DE69839264T2 (de) 2009-05-14
CN1494900A (zh) 2004-05-12
AU7436398A (en) 1998-11-13
CN1313082C (zh) 2007-05-02
HUP0004297A2 (hu) 2001-08-28
DE69839264D1 (de) 2008-04-30
PT980240E (pt) 2008-06-06
US6475507B1 (en) 2002-11-05
NO995063D0 (no) 1999-10-15
CZ297078B6 (cs) 2006-09-13
JP4557312B2 (ja) 2010-10-06
AR012448A1 (es) 2000-10-18
AU741964B2 (en) 2001-12-13
IL132217A0 (en) 2001-03-19
DK0980240T3 (da) 2008-07-28
CA2286575C (fr) 2012-06-05
CZ362699A3 (cs) 2000-04-12
PL196771B1 (pl) 2008-01-31
HK1027983A1 (en) 2001-02-02
JP2002500631A (ja) 2002-01-08
EP0980240B1 (fr) 2008-03-19
PL336296A1 (en) 2000-06-19
NO995063L (no) 1999-11-15
ES2303353T3 (es) 2008-08-01
US6217893B1 (en) 2001-04-17
CN1256628A (zh) 2000-06-14
ATE389388T1 (de) 2008-04-15
EP0980240A1 (fr) 2000-02-23
CN1144584C (zh) 2004-04-07
CA2286575A1 (fr) 1998-10-29
WO1998047489A1 (fr) 1998-10-29
AR061828A2 (es) 2008-09-24
NO327999B1 (no) 2009-11-09
TW577759B (en) 2004-03-01
MY118835A (en) 2005-01-31

Similar Documents

Publication Publication Date Title
BR9808933A (pt) Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo
BR9916053B1 (pt) composições contendo um peptìdeo e um ácido glicólico poliláctico, adequadas para preparação de implantes subcutáneos com perìodo de liberação prolongado.
IL157963A0 (en) Hsa-free formulations of interferon-beta
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
DE69934582D1 (de) Delavirdin tablettenformulierung
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
BR9916835A (pt) Composição de galantamina de liberação controlada
EA200000584A3 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
CA2346001A1 (en) Controlled release nanoparticulate compositions
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
BR9913857A (pt) Formulações de proteìna
NO20000284D0 (no) Tanninsyre-polymerblandinger for kontrollert frigivelse av farmasoeytiske midler, saerlig i munnhulen
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
ES2079389T3 (es) Dispersiones de polimeros liofilizados y su uso para preparar composiciones farmaceuticas de liberacion retardada.
DE60024414D1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
AU2002212395A1 (en) Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
DE60042972D1 (de) Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
RU2000113731A (ru) Пористые частицы гидроксиапатита в качестве носителей для лекарственных веществ
WO1999061014A3 (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
BR0008739A (pt) Composições de liberação controlada debeta-histina

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ O MESMO NAO ATENDE AO DISPOSTO NOS SEGUINTES ARTIGOS DALPI 9.279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]